Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15416509 | 0.98 | POLB (0.41) | POLBSMN1; SMN2MAPTHRH3HRH2 | |
| SCHEMBL18912350 | 0.90 | POLB (0.48) | POLBSMN1; SMN2HRH3ALDH1A1PKM | |
| SCHEMBL18893655 | 0.90 | POLB (0.48) | POLBSMN1; SMN2HRH3ALDH1A1PKM | |
| SCHEMBL18912395 | 0.90 | POLB (0.48) | POLBSMN1; SMN2HRH3ALDH1A1PKM | |
| SCHEMBL3106518 | 0.79 | TAAR1 (0.38) | — | |
| SCHEMBL26614772 | 0.79 | POLB (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL26614900 | 0.79 | POLB (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL3683539 | 0.77 | QPCT (0.32) | — | |
| SCHEMBL789463 | 0.77 | QPCT (0.32) | — | |
| SCHEMBL3095725 | 0.77 | KEAP1 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | PARP1, PARP11, PARP3 | POLB 77/4885SMN1; SMN2 1432/4885MAPT 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.